Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Kardiologia Polska (Polish Heart Journal)
MENU
Shortcuts Online first Submit an article Reviewers 2021 Zeszyty Edukacyjne Author Guidelines Licence terms

open access

Online first
Original article
Published online: 2022-05-16
View PDF Download PDF file Supp./Additional Files [1]
Get Citation

Pulmonary artery systolic pressure at 1-month predicts one-year survival after transcatheter aortic valve implantation

Anna Olasińska-Wiśniewska1, Kajetan Grodecki2, Tomasz Urbanowicz1, Bartłomiej Perek1, Marek Grygier3, Marcin Misterski1, Sebastian Stefaniak1, Tatiana Mularek-Kubzdel3, Maciej Lesiak3, Marek Jemielity1
DOI: 10.33963/KP.a2022.0128
·
Pubmed: 35575408
Affiliations
  1. Department of Cardiac Surgery and Transplantology, Poznan University of Medical Sciences, Poznań, Poland
  2. 1st Department of Cardiology, Medical University of Warsaw, Warszawa, Poland
  3. 1st Department of Cardiology, Poznan University of Medical Sciences, Poznań, Poland

open access

Online first
Original article
Published online: 2022-05-16

Abstract

BACKGROUND: Pulmonary hypertension related to left ventricle heart disease is a common finding in patients with severe aortic stenosis treated with transcatheter aortic valve implantation (TAVI) and is associated with higher mortality rate.

AIMS: The aim of the study was to analyze the influence of pulmonary artery systolic pressure (PASP) changes after TAVI on long-term survival.

METHODS: TAVI was performed in 362 patients between January 2013 and December 2018. Study group comprised 210 patients who underwent a detailed 1-month follow-up.

Results: At the 1-month, 142 had a stable or decrease in PASP value (Group-1), while in 68 patients an increase was observed (Group-2). During 1-year follow-up 20 patients died (9.5%), 9 in Group 1 and 11 in the Group 2 (P = 0.02). ROC curve analysis (area under the curve [AUC], 0.750) revealed a significant value of 1-month measurement for 1-year mortality prediction. The cut-off value for PASP value predictive for mortality was ≤41 mm Hg. Kaplan-Meier analysis showed significantly higher mortality in patients without a 1-month PASP decrease. In the multivariable analysis, PASP measured at 1-month after TAVI (hazard ratio, 1.040; 95% confidence interval, 1.019–1.062; P <0.001) was independent predictor of 1-year mortality. Each 1 mm Hg increase in PASP predicts a 4% increase in the risk of death.

CONCLUSION: Decreased or stable value of PASP at 1-month follow-up may predict better 1-year survival after TAVI, while each 1mmHG increase in PASP confers a 4% greater risk of 1-year mortality.

Abstract

BACKGROUND: Pulmonary hypertension related to left ventricle heart disease is a common finding in patients with severe aortic stenosis treated with transcatheter aortic valve implantation (TAVI) and is associated with higher mortality rate.

AIMS: The aim of the study was to analyze the influence of pulmonary artery systolic pressure (PASP) changes after TAVI on long-term survival.

METHODS: TAVI was performed in 362 patients between January 2013 and December 2018. Study group comprised 210 patients who underwent a detailed 1-month follow-up.

Results: At the 1-month, 142 had a stable or decrease in PASP value (Group-1), while in 68 patients an increase was observed (Group-2). During 1-year follow-up 20 patients died (9.5%), 9 in Group 1 and 11 in the Group 2 (P = 0.02). ROC curve analysis (area under the curve [AUC], 0.750) revealed a significant value of 1-month measurement for 1-year mortality prediction. The cut-off value for PASP value predictive for mortality was ≤41 mm Hg. Kaplan-Meier analysis showed significantly higher mortality in patients without a 1-month PASP decrease. In the multivariable analysis, PASP measured at 1-month after TAVI (hazard ratio, 1.040; 95% confidence interval, 1.019–1.062; P <0.001) was independent predictor of 1-year mortality. Each 1 mm Hg increase in PASP predicts a 4% increase in the risk of death.

CONCLUSION: Decreased or stable value of PASP at 1-month follow-up may predict better 1-year survival after TAVI, while each 1mmHG increase in PASP confers a 4% greater risk of 1-year mortality.

Full Text:

View PDF Download PDF file Supp./Additional Files [1]
Get Citation

Keywords

transcatheter, aortic stenosis, pulmonary artery systolic pressure, mortality

Supp./Additional Files (1)
Supplementary material
Download
68KB
About this article
Title

Pulmonary artery systolic pressure at 1-month predicts one-year survival after transcatheter aortic valve implantation

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Online first

Article type

Original article

Published online

2022-05-16

Page views

111

Article views/downloads

55

DOI

10.33963/KP.a2022.0128

Pubmed

35575408

Keywords

transcatheter
aortic stenosis
pulmonary artery systolic pressure
mortality

Authors

Anna Olasińska-Wiśniewska
Kajetan Grodecki
Tomasz Urbanowicz
Bartłomiej Perek
Marek Grygier
Marcin Misterski
Sebastian Stefaniak
Tatiana Mularek-Kubzdel
Maciej Lesiak
Marek Jemielity

References (34)
  1. Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Supplement. Eur Heart J. 2021; 43(7): 561–632.
    CrossRefPubMed
  2. Huczek Z, Rymuza B, Mazurek M, et al. Temporal trends of transcatheter aortic valve implantation in a high-volume academic center over 10 years. Kardiol Pol. 2021; 79(7-8): 820–826.
    CrossRefPubMed
  3. Dąbrowski M, Parma R, Huczek Z, et al. The Polish Interventional Cardiology TAVI Survey (PICTS): 10 years of transcatheter aortic valve implantation in Poland. The landscape after the first stage of the Valve for Life Initiative. Pol Arch Intern Med. 2021; 131(5): 413–420.
    CrossRefPubMed
  4. Dębiński M, Domaradzki W, Fil W, et al. Long‑term outcomes of transcatheter self-expanding aortic valve implantations in inoperable and high surgical-risk patients with severe aortic stenosis: a single-center single-valve registry. Kardiol Pol. 2021; 79(3): 319–326.
    CrossRefPubMed
  5. Urbanowicz T, Staburzyńska-Migaj E, Pawłowska M, et al. EuroSCORE is a predictor of postoperative pericardial effusion following heart transplantation. Ann Transplant. 2015; 20: 193–197.
    CrossRefPubMed
  6. Ludwig S, Goßling A, Seiffert M, et al. Risk prediction in patients with low-flow, low-gradient aortic stenosis and reduced ejection fraction undergoing TAVI. Open Heart. 2022; 9(1).
    CrossRefPubMed
  7. Olasińska-Wiśniewska A, Perek B, Grygier M, et al. Increased neutrophil-to-lymphocyte ratio is associated with higher incidence of acute kidney injury and worse survival after transcatheter aortic valve implantation. Cardiol J. 2021 [Epub ahead of print].
    CrossRefPubMed
  8. Baştuğ S, Çöteli C, Çelik MC, et al. Baseline anemia is an independent predictor of long-term mortality in patients undergoing transcatheter aortic valve implantation. Angiology. 2022; 73(1): 26–32.
    CrossRefPubMed
  9. Al-Khadra Y, Darmoch F, Moussa Pacha H, et al. The outcomes of pulmonary hypertension patients with severe aortic stenosis who underwent surgical aortic valve replacement or transcatheter aortic valve implantation. Am J Cardiol. 2019; 124(4): 586–593.
    CrossRefPubMed
  10. Garcia-Ribas C, Ble M, Gómez M, et al. Importance of tricuspid regurgitation velocity threshold in risk assessment of pulmonary hypertension-long-term outcome of patients submitted to aortic valve replacement. Front Cardiovasc Med. 2021; 8: 720643.
    CrossRefPubMed
  11. Levy F, Bohbot Y, Sanhadji K, et al. Impact of pulmonary hypertension on long-term outcome in patients with severe aortic stenosis. Eur Heart J Cardiovasc Imaging. 2018; 19(5): 553–561.
    CrossRefPubMed
  12. Tchetche D, Van der Boon RMA, Dumonteil N, et al. Adverse impact of bleeding and transfusion on the outcome post-transcatheter aortic valve implantation: insights from the Pooled-RotterdAm-Milano-Toulouse In Collaboration Plus (PRAGMATIC Plus) initiative. Am Heart J. 2012; 164(3): 402–409.
    CrossRefPubMed
  13. Czerwińska-Jelonkiewicz K, Łętowska M, Witkowski A, et al. Significance of the age of transfused blood for prognosis after transcatheter aortic valve implantation. Pol Arch Intern Med. 2017; 127(7-8): 490–487.
    CrossRefPubMed
  14. Özdemir E, Esen Ş, Emren SV, et al. Association between Intermountain Risk Score and long-term mortality with the transcatheter aortic valve implantation procedure. Kardiol Pol. 2021; 79(11): 1215–1222.
    CrossRefPubMed
  15. Urbanowicz TK, Michalak M, Gąsecka A, et al. A risk score for predicting long-term mortality following off-pump coronary artery bypass grafting. J Clin Med. 2021; 10(14).
    CrossRefPubMed
  16. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016; 37(1): 67–119.
    CrossRefPubMed
  17. Fang JC, DeMarco T, Givertz MM, et al. World Health Organization Pulmonary Hypertension group 2: pulmonary hypertension due to left heart disease in the adult--a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2012; 31(9): 913–933.
    CrossRefPubMed
  18. Pardo Sanz A, Santoro C, Hinojar R, et al. Right ventricle assessment in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation. Echocardiography. 2020; 37(4): 586–591.
    CrossRefPubMed
  19. Kleczynski P, Dziewierz A, Wiktorowicz A, et al. Prognostic value of tricuspid regurgitation velocity and probability of pulmonary hypertension in patients undergoing transcatheter aortic valve implantation. Int J Cardiovasc Imaging. 2017; 33(12): 1931–1938.
    CrossRefPubMed
  20. Roselli EE, Abdel Azim A, Houghtaling PL, et al. Pulmonary hypertension is associated with worse early and late outcomes after aortic valve replacement: implications for transcatheter aortic valve replacement. J Thorac Cardiovasc Surg. 2012; 144(5): 1067–1074.e2.
    CrossRefPubMed
  21. Baumgartner H, Iung B, Otto CM. Timing of intervention in asymptomatic patients with valvular heart disease. Eur Heart J. 2020; 41(45): 4349–4356.
    CrossRefPubMed
  22. Ben-Dor I, Goldstein SA, Pichard AD, et al. Clinical profile, prognostic implication, and response to treatment of pulmonary hypertension in patients with severe aortic stenosis. Am J Cardiol. 2011; 107(7): 1046–1051.
    CrossRefPubMed
  23. Lindman BR, Zajarias A, Maniar HS, et al. Risk stratification in patients with pulmonary hypertension undergoing transcatheter aortic valve replacement. Heart. 2015; 101(20): 1656–1664.
    CrossRefPubMed
  24. Sinning JM, Hammerstingl C, Chin D, et al. Decrease of pulmonary hypertension impacts on prognosis after transcatheter aortic valve replacement. EuroIntervention. 2014; 9(9): 1042–1049.
    CrossRefPubMed
  25. O'Sullivan CJ, Montalbetti M, Zbinden R, et al. Screening for pulmonary hypertension with multidetector computed tomography among patients with severe aortic stenosis undergoing transcatheter aortic valve implantation. Front Cardiovasc Med. 2018; 5: 63.
    CrossRefPubMed
  26. Kokkinidis DG, Papanastasiou CA, Jonnalagadda AK, et al. The predictive value of baseline pulmonary hypertension in early and long term cardiac and all-cause mortality after transcatheter aortic valve implantation for patients with severe aortic valve stenosis: A systematic review and meta-analysis. Cardiovasc Revasc Med. 2018; 19(7 Pt B): 859–867.
    CrossRefPubMed
  27. Tang M, Liu X, Lin C, et al. Meta-Analysis of outcomes and evolution of pulmonary hypertension before and after transcatheter aortic valve implantation. Am J Cardiol. 2017; 119(1): 91–99.
    CrossRefPubMed
  28. Nijenhuis VJ, Huitema MP, Vorselaars VMM, et al. Echocardiographic pulmonary hypertension probability is associated with clinical outcomes after transcatheter aortic valve implantation. Int J Cardiol. 2016; 225: 218–225.
    CrossRefPubMed
  29. Luçon A, Oger E, Bedossa M, et al. Prognostic implications of pulmonary hypertension in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation: study from the FRANCE 2 Registry. Circ Cardiovasc Interv. 2014; 7(2): 240–247.
    CrossRefPubMed
  30. Scisło P, Grodecki K, Rymuza B, et al. Impact of transcatheter aortic valve implantation on coexistent mitral regurgitation parameters. Kardiol Pol. 2021; 79(2): 179–184.
    CrossRefPubMed
  31. Wilbring M, Tugtekin SM, Ritzmann M, et al. Transcatheter aortic valve implantation reduces grade of concomitant mitral and tricuspid valve regurgitation and pulmonary hypertension. Eur J Cardiothorac Surg. 2014; 46(5): 818–824.
    CrossRefPubMed
  32. Medvedofsky D, Klempfner R, Fefer P, et al. The significance of pulmonary arterial hypertension pre- and post-transfemoral aortic valve implantation for severe aortic stenosis. J Cardiol. 2015; 65(4): 337–342.
    CrossRefPubMed
  33. O'Sullivan CJ, Wenaweser P, Ceylan O, et al. Effect of pulmonary hypertension hemodynamic presentation on clinical outcomes in patients with severe symptomatic aortic valve stenosis undergoing transcatheter aortic valve implantation: insights from the new proposed pulmonary hypertension classification. Circ Cardiovasc Interv. 2015; 8(7): e002358.
    CrossRefPubMed
  34. Sultan I, Fukui M, Bianco V, et al. Impact of combined pre and postcapillary pulmonary hypertension on survival after transcatheter aortic valve implantation. Am J Cardiol. 2020; 131: 60–66.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Sp. z o.o. VM Group Sp.k., ul. Świętokrzyska 73 , 80–180 Gdańsk, Poland

phone:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl